Universidad del Quindio
Centro de Investigaciones Biomédicas
Medical degree from the University of Quindio with a Master degree in Tropical Biomedicine (MSc) from the Institute of Tropical Medicine Antwerp (Belgium), Doctorate degree (PhD) in Parasite Biology from the University of Reims (France). Postdoctoral in Biomolecular Spectroscopy from the Institute of Biomolecular of the University of Reims (France). Director of the Molecular Parasitology Group (GEPAMOL) at the Universidad del Quindio (Colombia, South America). Avenida Bolivar 12N Armenia (Quindio) Colombia. Past- Dean of the Faculty of Health Sciences, University of Quindio 2015-2018. Past- Vicepresident of Research Universidad del Quindio 2018-2020. Editor in chief of Infectio (Official Journal of Colombian Association of Infectious Diseases, ISSN 0123-9392) and member of the editorial Board, International Journal of Food Microbiology. Associated Editor of BMC Infectious Diseases. Guest Associated Editor of the Journal Frontiers in Cellular and Infection Microbiology, Frontiers in Emerging Tropical Diseases and PLoS Neglected Tropical Diseases. International Ambassador of the American Society of Microbiology (ASM) 2018-2020.In parasitology he described the current epidemiological situation of congenital and ocular toxoplasmosis in Colombia, the main risk factors associated to the acquisition of this disease, performed evaluation and validation of diagnosis tests and lead the elaboration of national evidence- based guidelines for congenital toxoplasmosis. His group pioneered the study of the role of parasite virulent factors in human disease and also identified cytokines linked to disease manifestations in ocular toxoplasmosis. In 2012 was invited to be part of the FAO and WHO Expert Meeting on Food-borne Parasites. In July 2013 he was nominated for the WHO expert elicitation on foodborne diseases on toxoplasmosis. He is particularly interested into develop methods to monitoring and control waterborne and food protozoa and in developing vaccines and new drugs for human toxoplasmosis.

Moderator of 1 Session

Video On-Demand
Session Type
Video On-Demand
Date
08/21/2022
Session Time
18:00 - 21:00
Room
Video On-Demand

Presenter of 3 Presentations

Video On-Demand

CHAIR INTRODUCTION (ID 2080)

Session Type
Video On-Demand
Date
08/21/2022
Session Time
18:00 - 21:00
Room
Video On-Demand
Lecture Time
18:10 - 18:30
Onsite or Pre-Recorded
Pre-Recorded
Video On-Demand

CLINICAL STUDIES OF THE ASSOCIATION BETWEEN TOXOPLASMOSIS AND MENTAL DISEASES (ID 1494)

Session Type
Video On-Demand
Date
08/21/2022
Session Time
18:00 - 21:00
Room
Video On-Demand
Lecture Time
19:10 - 19:30
Onsite or Pre-Recorded
Pre-Recorded
02. Parasites of humans

PRE-RECORDED: REQUIREMENTS FOR CLINICAL TRIALS OF A VACCINE CANDIDATE FOR HUMAN TOXOPLASMOSIS (ID 1803)

Session Type
02. Parasites of humans
Date
08/22/2022
Session Time
15:00 - 16:30
Room
Auditorium 10
Lecture Time
16:03 - 16:26
Presentation Icon
Pre-Recorded Presentation
Onsite or Pre-Recorded
Pre-Recorded

Abstract

Abstract Body

We have now many promising vaccine candidates for toxoplasmosis that can be assayed in human clinical trials. They have been evaluated in different animal models, including mice, rabbit and monkeys, achieving diverse levels of protection. The more promising are vaccines based on live attenuated parasites and total antigen preparations or subunit vaccine (selected protein fragments obtained through recombinant protein methodology or expressed through nucleic acid vaccine based platforms). Clinical trials in human could have as primary outcome the reduction of congenital toxoplasmosis in non-immune human populations or the reduction of new chorioretinal scars. Secondary outcomes could be the induction of specific CD8+ T cells and CD4+ specific memory cells. I will discuss during this conference the main challenges and barriers to launch human clinical trial for toxoplasmosis.

Hide